Renal and cardiac effects of renal sympathetic denervation and carotid baroreceptor stimulation

Current Vascular Pharmacology

Volumn 12, Issue 1, 2014, Pages 55-62

  Tsioufis, Costas ^a   Dimitriadis, Kyriakos ^a   Thomopoulos, Costas ^a   Doumas, Michalis ^b   Papademetriou, Vasilios ^c   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

BAT and cardiorenal damage; RSD

Indexed keywords

ADENOSINE; ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; ATROPINE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYSTATIN C; DOPAMINE; NITRIC OXIDE; NORADRENALIN; RAMIPRIL; SODIUM; TELMISARTAN;

ADRENERGIC SYSTEM; ARTICLE; BAROREFLEX ACTIVATION THERAPY; CAROTID SINUS PRESSORECEPTOR; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY INJURY; KIDNEY ISCHEMIA; NEUROLOGICAL AND SENSORIAL PROCEDURES; NONHUMAN; SENSORY STIMULATION;

ANIMALS; BAROREFLEX; CARDIOVASCULAR DISEASES; CAROTID SINUS; ELECTRIC STIMULATION THERAPY; HEART FAILURE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84897416770     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990144     Document Type: Article

References (124)

1. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34: 724-8.
2. Masuo K, Lambert G, Esler M, Rakugi H, Ogihara T, Schlaich M. The role of sympathetic nervous acitivity in renal injury and endstage renal disease. Hypertens Res 2010; 33: 521-8.
3. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 31: 819-23.
4. Tsioufis C, Kordalis A, Flessas D, et al. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens 2011; 2011: 642416.
5. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982; 49: 1659-66.
6. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effects of cardiac sympathetic nerve activity on mode of death in congestive heart failure. Eur Heart J 2001; 22: 1136-43.
7. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-9.
8. Sobotka PA, Krum H, Bohm M, Francis DP, Sclaich MP. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep 2012: epub ahead of print: DOI 10.1007/s11886-012-0258-x.
9. Papademetriou V, Doumas M, Faselis M, et al. Carotid baroreceptor stimulation for the treatment of resistant hypertension. Int J Hypertens 2011; 2011: 964394.
10. Georgakopoulos D, Little W, Abraham W, Weaver F, Zile M. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Cardiac Fail 2011; 17: 167-78.
11. Schlaich MP, Socratous F, Hennebry S, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2009; 20: 933-9.
12. Masuo K, Mikami H, Ogihara T, Tuck M. Hormonal mechanisms in blood pressure reduction during hemodialysis in patients with chronic renal failure. Hypertens Res 1995; 18: 201-3.
13. Grassi G, Quarti Trevano F, Seravalle G, et al. Early sympathetic activation in the initial stages of chronic renal failure. Hypertension 2011; 57: 846-51.
14. Masuo K, Katsuya T, Sugimoto K, et al. High plasma norepinephrine levels associated with β2-adrenoreceptor polymorphisms predict future renal damage in nonobese normotensive individuals. Hypertens Res 2007; 30: 503-11.
15. Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML. Beta2-adrenoreceptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation 2005; 111: 3429-34.
16. Masuo K, Katsuya T, Kawaguchi H, et al. Beta2-and beta3-adrenoreceptor polymorphisms relate to subsequent weight gain and blood pressure elevation in obese normotensive individuals. Hypertens Res 2006; 29: 951-59.
17. Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, et al. Influence of sympathetic activity on blood pressure and vascular damage evaluated by means of urinary albumin excretion. J Clin Hypertens (Greenwich) 2006; 8: 619-24.
18. Rao F, Wessel J, Wen G, Zhang L, et al. Renal albumin excretion. Twin studies identify influences of heredity, environment, and adrenergic pathway polymorphism. Hypertension 2007; 49: 1015-31.
19. Klein IH, Ligtenberg G, Neumann J, et al. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14: 3239-44.
20. Miyajima E, Yamada Y, Toshiba Y, et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1997; 17: 1057-62.
21. Johansson M, Elam M, Rundqvist B, et al. Increased sympathetic nerve activity in renovascular hypertension. Circulation 1999; 99: 2537-42.
22. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 2010; 6: 82-90.
23. Bruno RM, Sudano I, Ghiadoni L, et al. Interactions between sympathetic nervous system and endogenous endothelin in patients with essential hypertension. Hypertension 2011; 57: 79-84.
24. Grassi G, Seravalle G, Ghiadoni L, et al. Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2620-7.
25. Hausberg M, Grassi G. Mechanisms of sympathetic overactivity in patients with chronic renal failure: a role for chemoreflex activation? J Hypertens 2007; 25: 47-9.
26. Recordati G, Zorzoli F, Pontara O, Turolo L, Zanchetti A. Factors influencing acute ischemia-induced renal hypertension in rats. J Hypertens 2002; 20: 2453-63.
27. Ye S, Nosrati S, Campese VM. Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF). J Clin Invest 1997; 99: 540-8.
28. Hering D, Zdrojewski Z, Krol E, et al. Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure. J Hypertens 2007; 25: 157-61.
29. Vink EE, Blankestijn. Evidence and consequences of the central role of the kidneys in the pathophysiology of sympathetic hyperactivity. Front Physiol 2012; 3: 29: Epub 2012 Feb 20.
30. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance and treatment. Kidney Int 2004; 65: 1568-76.
31. Siddiqi L, Joles JA, Grassi G, Blankestijn PJ. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? J Hypertens 2009; 27: 1341-9.
32. Katholi RE, Whitlow PL, Hageman GR, Woods WT. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via renal nerves in the dog. J Hypertens 1984; 2: 34959.
33. DiBona GF. Neural control of the kidney: functionally specific renal sympathetic nerve fibers. Am K Physiol Regul Integr Comp Physiol 2000; 279: 1517-24.
34. Reid IA. Interactions between ANG II, sympathetic nervous system and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992; 262: 763-78.
35. DiBona GF. Central sympathoexcitatory actions of angiotensin II: role of type 1 angiotensin II receptors. J Am Soc Nephrol 1999; 10: 90-4.
36. Brooks VL, Osborn JW. Hormonal-sympathetic interactions in long-term regulation of arterial pressure: an hypothesis. Am J Physiol 1995; 268: 1343-58.
37. DiBona GF. Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function. Hypertension 2000; 36: 1083-8.
38. Zhang ZH, Kang YY, Wei SG, Felder RB. Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am J Physiol Heart Circ Physiol 2008; 294: 1067-74.
39. Uhr M, Holsboer F, Muller MB. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol 2002; 14: 753-9.
40. Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease. Nephrol Dial Transplant 2004; 19: 1354-7.
41. Amann K, Koch A, Hofstetter J, et al. Glomerulosclerosis and progression: effect of subantihypertensive doses of alfa and beta blockers. Kidney Int 2011; 60: 1309-23.
42. Patel MB, Sterwart JM, Loud AV, et al. Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 1991; 84: 2091-100.
43. Briest W, Homagk L, Rassler B, et al. Norepinephrine-induced changes in cardiac transforming growth factor-beta isoform expression pattern of female and male rats. Hypertension 2004; 44: 410-8.
44. Levick SP, Murray DB, Janicki JS, Brower GL. Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension 2010; 55: 270-6.
45. Perlini S, Palladini G, Ferrero I, et al. Sympathectomy or doxazocin but not propranolol, blunt myocardial interstitial fibrosis in pressure overload hypertrophy. Hypertension 2005; 46: 1213-8.
46. Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108: 560-5.
47. Greenwood JP, Scott EM, Stroker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol. 2001; 38: 1711-7.
48. Burns J, Sivananthan MU, Ball G, Mackintosh AF, Mary D, Greenwood JP. Relationships between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation 2007; 115: 1999-2005.
49. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012; 33(9): 1058-66.
50. Azevedo ER, Newton GE, Floras JS, Parker JD. Reducing cardiac filling pressure lowers norepinephrine spillover in patients with chronic heart failure. Circulation 2000; 101: 2053-9.
51. Sopher SM, Smith ML, Eckberg DL, Fritsch JM, Dibner-dunlap ME. Autonomic pathophysiology in heart failure: carotid baroreceptors-cardiac reflexes. Am J Physiol Heart Circ Physiol 1990; 259: 689-96.
52. Toussaint JF, Koeling TM, Shmidt CJ, Kwong KK, LaRaia PJ, Kantor HL. Local relation between oxidative metabolism and perfusion in leg muscles of patients with heart failure studies by magnetic resonance impaling and spectroscopy. J Heart Lung Transplant 1998; 17: 892-900.
53. Levy BI, Schiffrin EL, Mourad JJ, et al. Impaired tissue perfusion: a pathology common to hypertension, obesity and diabetes mellitus. Circulation 2008; 118: 968-76.
54. Malpas S. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev 2010; 90: 513-57.
55. Lehnart SE, Wehrens XH, Marks AR. Calstabin deficiency, ryanodine receptors and sudden cardiac death. Biochem Biophys Res Commun 2004; 322: 1267-79.
56. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 1995; 92: 3206-11.
57. Grassi G, Seravalle G, Bertinieri G, et al. Sympathetic and reflex abnormalities in heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Clin Sci (Lond) 2001; 101: 141-6.
58. Grassi G, Seravalle G, Dell'Oro R, et al. Sympathetic and baroreflex function in hypertensive or heart failure patients with ventricular arrhythmias. J Hypertens. 2004; 22: 1747-53.
59. Brunner-La Rocca HP, Esler MD, et al. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J. 2001; 22: 1136-43.
60. Grassi G, Seravalle G, Bertinieri G, Mancia G. Behaviour of the adrenergic cardiovascular drive in atrial fibrillation and cardiac arrhythmias. Acta Physiol Scand 2003; 177: 399-404.
61. Grassi G, Seravalle G, Quarti-Trevano F, et al. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension 2003; 42: 873-7.
62. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77: 75-197.
63. Lohmeier TE, Hildebrandt DA, Dwyer TM, et al. Renal denervation does not abolish sustained baroreflex reductions in arterial pressure. Hypertension 2007; 49: 373-79.
64. Lohmeier TE, Dwyer TM, Irwin ED, Rossing MA, Kieval RS. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension 2007; 49: 1307-14.
65. Just A, Wittmann U, Ehmke H, Kirchheim HR. Autoregulation of renal blood flow in the conscious dog and the contribution of the tubuloglomerular feedback. J Physiol 1998; 506: 275-90.
66. Cowley AW. Role of the renal medulla in volume and arterial pressure regulation. Am J Physiol Regul Integr Comp Physiol 1997; 273: 1-15.
67. Matson DL, Lu S, Nakanishi K, Papanek PE, Cowley AW. Effect of chronic renal medullary intric oxide inhibition on blood pressure. Am J Physiol Regul Integr Comp Physiol 1994; 266: 1918-26.
68. Sica D, Rothstein M, Bisognano JD, et al. Baroreflex activation therapy preserves eGFR in hypertensive patients with stage 2 and 3 chronic kidney disease: results from European and United States trials of the Rheos System. J Am Soc Nephrol 2009; 20: 11A.
69. Bakris GL, Nadim M, Georgakopoulos D, Sica D. Electrical stimulation of the carotid baroreceptors using the Rheos System decreased renal artery stiffness. J Am Soc Nephrol 2009; 20: 1A.
70. Mitchell GF. Clinical achievents of impedance analysis. Med Biol Eng Comput 2009; 47: 153-63.
71. Loutzenhiser R, Bidani A, Chilton L. Renal myogenic response: kinetic attributes and physiological role. Circ Res 2002; 90: 1316-24.
72. Wustmann K, Kucera J, Scheffers I, et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009; 54: 530-6.
73. Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function and blood pressure in hypertensive patients. Hypertension 2010; 55: 619-26.
74. Bisognano J, Bakris G, Nadim M, Sanchez L, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension. J Am Coll Cardiol 2011; 58: 765-73.
75. Nagasu H, Satoh M, Kuwabara A, et al. Renal denervation reduces glomerular injury by suppressing NAD(P)H oxidase activity in Dahl salt sensitive rats. Nephrol Dial Transplant 2010; 25: 2889-98.
76. Modlinger P, Wilcox C, Aslam S. Nitric oxide, oxidative stress and progression of chronic renal failure. Semin Nephrol 2004; 24: 354-65.
77. Veelken R, Vogel E, Hilgers K, et al. Autonomic renal denervation ameliorates experimental glomerulonephritis. J Am Soc Nephrol 2008; 19: 1371-8.
78. Abu-Amarah I, Ajikobi DO, Bachelard H, Cupples WA, Salevsky FC. Responses of mesenteric and renal blood flow dynamics to acute denervation in anesthetized rats. Am J Physiol Regul Integr Comp Physiol 1998; 275: 1543-52.
79. Just A, Wittmann U, Ehmke H, Kirchheim HR. Autoregulation of renal blood flow in the conscious dog and the contribution of the tubule-glomerular feedback. J Physiol 1998; 506: 275-90.
80. Osborn JL, Francisco LL. DiBona GF. Effect of renal nerve stimulation on renal blood flow autoregulation and antinatriuresis during reduction in renal perfusion pressure. Proc Soc Exp Biol Med 1981; 168: 77-81.
81. DiBona G, Sawin LL. Effect of renal denervation on dynamic autoregulation of renal blood flow. Am J Physiol Renal Physiol 2004; 286: 1209-18.
82. Malpas SC, Evans RG. Do different levels and patterns of sympathetic activation all provoke renal vasoconstriction? J Auton Nerv Syst 1998; 69: 72-82.
83. Malpas SC, Evans RG, Head GA, Lukoshkova EV. Contribution of renal nerves to renal blood flow variability during hemorrhage. Am J Physiol Regul Integr Comp Physiol 1998; 274: 1283-94.
84. Kompanowska-Jezierska E, Walkowska A, Johns EJ, Sadowski J. Early effects of renal denervation in the anaesthetized rat: natriuresis and increased cortical blood flow. J Physiol 2001; 531: 527-34.
85. Barret CJ, Navakatikyan MA, Malpas SC. Long-term control of renal blood flow: what is the role of the renal nerves? Am J Physiol Regul Integr Comp Physiol 2001; 280: 1534-45.
86. Salman IM, Sattar MA, Abdullah NA, et al. Renal functional and hemodynamic changes following acute unilateral renal denervation in Sprague Dawley rats. Indian J Med Res 2010; 131: 76-82.
87. Tsioufis C, Papademetriou V, Dimitriadis K, et al. Chronic effects of percutaneous renal sympathetic denervation on renal hemodynamics and plasma norepinephrine levels using a novel catheter forradiofrequency ablation. J Am Coll Cardiol 2012; 59: E1709.
88. Manoharan J, Pijls NH, Lameire N, et al. Assessment of renal flow and flow reserve in humans. J Am Coll Cardiol 2006; 47: 620-25.
89. Hussain T, Lokhandwala MF. Renal dopamine receptor function in hypertension. Hypertension 1998; 32: 187-97.
90. Murphy MB. Dopamine: a role in the pathogenesis and treatment of hypertension. J Hum Hypertens 2000; 14: S47-S50.
91. Vane DW, Weber TR, Careskey J, Grosfeld JL. Systemic and renal effects of dopamine in the infant pig. J Clin Res 1982; 32: 477-83.
92. Schmieder RE, Redon J, Grassi G, et al. ESH position paper: renal denervation-an interventional therapy of resistant hypertension. J Hypertens 2012; 30: 837-41.
93. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.
94. Krum H, Barman N, Schlaich M, et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-17.
95. Petidis K, Anyfanti P, Doumas M. Renal sympathetic denervation: renal function concerns. Hypertension 2011: 58: e19.
96. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET Study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-53.
97. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach-National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-61.
98. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-9.
99. Worthley S, Worthley M, Sinhal A, et al. EnligHTN I: One-Month Data Safety and efficacy of a novel multi-electrode renal denervation catheter in patients with resistant hypertension: a first-in-man multi-center study. PCR 2012.
100. Hering D, Walton AS, Krum H, et al. Renal denervation in moderate to severe chronic kidney disease. J Am Soc Nephrol 2012; May 17 [Epub ahead of print].
101. Prochnau D, Lauten A, Busch M, Kuehnert H, Figulla HR, Surber R. Catheter-based radiofrequency ablation therapy of the renal sympathetic-nerve system for drug resistant hypertension in a patient with end-stage renal disease. Int J Cardiol, 2011 May 31. [Epub ahead of print].
102. Schlaich MP, Straznicky N, Grima M, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens. 2011 May; 29(5): 991-6.
103. Georgakopoulos D, Wagner D, Cates AW, Irwin E, Lovett EG. Effects of electrical stimulation of the carotid sinus baroreflex using the Rheos device on ventricular-vascular coupling and myocardial insufficiency assessed by pressure-volume relations in nonvagotomized anesthetized dogs. Conf Proc IEEE Eng Med Biol Soc 2009; 2009: 2025-9.
104. Eckberg DL, Fletcher GF, Braunwald E. Mechanisms of prolongation of the R-R interval with electrical stimulation of the carotid sinus nerves in man. Circ Res 1972; 30: 131-8.
105. Braunwald E, Vatner SF, Braunwald NS, Sobel BE. Carotid sinus nerve stimulation in the treatment of angina pectoris and supraventricular tachycardia. Calif Med 1970; 112: 41-50.
106. Phan TT, Abozguia K, Shivu GN, et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol 2009; 54: 402-9.
107. Zucker IH, Hackely JF, Cornish KG, et al. Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension 2007; 50: 904-10.
108. Sabbah H, Gupta R, Imai M, et al. Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail 2011; 4: 65-70.
109. Villareal RP, Liu BC, Massumi A. Heart rate variability and cardiovascular mortality. Curr Atheroscler Rep. 2002; 4(2): 120-7.
110. Bisognano JD, Kaufman CL, Bach DS, et al. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension. J Am Coll Cardiol 2011; 57: 1787-8.
111. Wachtell K, Dahlof B, Rokkedal J, et al. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the losartan intervention for endpoint reduction in hypertension study. Am Heart J 2002; 144: 1057-64.
112. Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg vs enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465-75.
113. Doumas M, Faselis C, Tsioufis C, Papademetriou V. Carotid baroreceptor activation for the treatment of resistant hypertension and heart failure. Curr Hypertens Rep 2012; Mar 29: Epub ahead of print.
114. Bisognano JD, de Leeuw P, Bach DS. Improved functional capacity and cardiovascular structure after baroreflex activation therapy in resistant hypertension patients with symptomatic heart failure: results from European and United States trials of the Rheos system. J Cardiac Fail 2009; 15: S63.
115. Barnes MM, Dorsch MP, Hummel SL, Koelling TM, Bleske BE. Treatment of heart failure with preserved ejection fraction. Pharmacotherapy 2011; 31: 312-31.
116. Karunaratne H, Muluk S, Papademetriou V, et al. Implantation of a carotid baroreceptor stimulator in patients with pacemakers and hypertension. Pacing Clin Electrophysiol 2011; 34: 354-56.
117. Sanchez L, Illlig K, Levy M, et al. Implantable carotid sinus stimulator for the treatment of resistant hypertension: local effects on carotid artery morphology. Ann Vasc Surg 2010; 24: 178-84.
118. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-4.
119. Schlaich M, Hering D, Sobotka P, Krum H, Esler M. Renal denervation in human hypertension: mechanism, current findings and future prospects. Curr Hypertens Rep 2012: Mar 29: Epub ahead of print.
120. Brandt M, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-9.
121. Mahfoud F, Schlaich M, Kindermann I, et al. Catheter-based renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940-6.
122. Diez J, Querejeta R, Lopez B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-7.
123. Zile MR, Little W. Effects of autonomic modulation. J Am Coll Cardiol 2012; 59: 910-1.
124. Eppel GA, Luff SE, Denton KM, Evans RG. Type 1 neuropeptide Y receptors and alpha-1 adrenoreceptors in the neural control of regional renal perfusion. Am J Physiol 2006; 290: 331-40.